Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation

Roble Bedolla, Thomas J. Prihoda, Jeffrey I. Kreisberg, Shazli N. Malik, Naveen K. Krishnegowda, Dean A. Troyer, Paramita M Ghosh

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Purpose: A considerable fraction of patients who undergo radical prostatectomy as treatment for primary prostate cancer experience biochemical recurrence detected by elevated serum levels of prostate-specific antigen. In this study, we investigate whether loss of expression of the tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and the phosphorylated form of the cell survival protein Akt (pAkt) predicts biochemical recurrence. Experimental Design: Expression of PTEN and pAkt was detected by immunohistochemistry in paraffin-embedded prostate cancer tissue obtained from men undergoing radical prostatectomy. Outcome was determined by 60-month follow-up determining serum prostate-specific antigen levels. Results: By itself, PTEN was not a good predictor of biochemical recurrence; however, in combination with pAkt, it was a better predictor of the risk of biochemical recurrence compared with pAkt alone. Ninety percent of all cases with high pAkt and negative PTEN were recurrent whereas 88.2% of those with low pAkt and positive PTEN were nonrecurrent. In addition, high Gleason scores resulted in reduced protection from decreased pAkt and increased PTEN. By univariate logistic regression, pAkt alone gives an area under the receiver-operator characteristic curve of 0.82 whereas the area under the receiver-operator characteristic curve for the combination of PTEN, pAkt, and Gleason based on a stepwise selection model is 0.89, indicating excellent discrimination. Conclusions: Our results indicate that loss of PTEN expression, together with increased Akt phosphorylation and Gleason score, is of significant predictive value for determining, at the time of prostatectomy, the risk of biochemical recurrence.

Original languageEnglish (US)
Pages (from-to)3860-3867
Number of pages8
JournalClinical Cancer Research
Volume13
Issue number13
DOIs
StatePublished - Jul 1 2007

Fingerprint

Prostatic Neoplasms
Recurrence
Prostatectomy
PTEN Phosphohydrolase
Proteins
Neoplasm Grading
Prostate-Specific Antigen
Chromosomes, Human, Pair 10
Serum
Phosphoric Monoester Hydrolases
Paraffin
Cell Survival
Research Design
Logistic Models
Immunohistochemistry
Phosphorylation
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. / Bedolla, Roble; Prihoda, Thomas J.; Kreisberg, Jeffrey I.; Malik, Shazli N.; Krishnegowda, Naveen K.; Troyer, Dean A.; Ghosh, Paramita M.

In: Clinical Cancer Research, Vol. 13, No. 13, 01.07.2007, p. 3860-3867.

Research output: Contribution to journalArticle

Bedolla, Roble ; Prihoda, Thomas J. ; Kreisberg, Jeffrey I. ; Malik, Shazli N. ; Krishnegowda, Naveen K. ; Troyer, Dean A. ; Ghosh, Paramita M. / Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 13. pp. 3860-3867.
@article{cf33b3b2f63440f1bb496d7fa77af4ec,
title = "Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation",
abstract = "Purpose: A considerable fraction of patients who undergo radical prostatectomy as treatment for primary prostate cancer experience biochemical recurrence detected by elevated serum levels of prostate-specific antigen. In this study, we investigate whether loss of expression of the tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and the phosphorylated form of the cell survival protein Akt (pAkt) predicts biochemical recurrence. Experimental Design: Expression of PTEN and pAkt was detected by immunohistochemistry in paraffin-embedded prostate cancer tissue obtained from men undergoing radical prostatectomy. Outcome was determined by 60-month follow-up determining serum prostate-specific antigen levels. Results: By itself, PTEN was not a good predictor of biochemical recurrence; however, in combination with pAkt, it was a better predictor of the risk of biochemical recurrence compared with pAkt alone. Ninety percent of all cases with high pAkt and negative PTEN were recurrent whereas 88.2{\%} of those with low pAkt and positive PTEN were nonrecurrent. In addition, high Gleason scores resulted in reduced protection from decreased pAkt and increased PTEN. By univariate logistic regression, pAkt alone gives an area under the receiver-operator characteristic curve of 0.82 whereas the area under the receiver-operator characteristic curve for the combination of PTEN, pAkt, and Gleason based on a stepwise selection model is 0.89, indicating excellent discrimination. Conclusions: Our results indicate that loss of PTEN expression, together with increased Akt phosphorylation and Gleason score, is of significant predictive value for determining, at the time of prostatectomy, the risk of biochemical recurrence.",
author = "Roble Bedolla and Prihoda, {Thomas J.} and Kreisberg, {Jeffrey I.} and Malik, {Shazli N.} and Krishnegowda, {Naveen K.} and Troyer, {Dean A.} and Ghosh, {Paramita M}",
year = "2007",
month = "7",
day = "1",
doi = "10.1158/1078-0432.CCR-07-0091",
language = "English (US)",
volume = "13",
pages = "3860--3867",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation

AU - Bedolla, Roble

AU - Prihoda, Thomas J.

AU - Kreisberg, Jeffrey I.

AU - Malik, Shazli N.

AU - Krishnegowda, Naveen K.

AU - Troyer, Dean A.

AU - Ghosh, Paramita M

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Purpose: A considerable fraction of patients who undergo radical prostatectomy as treatment for primary prostate cancer experience biochemical recurrence detected by elevated serum levels of prostate-specific antigen. In this study, we investigate whether loss of expression of the tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and the phosphorylated form of the cell survival protein Akt (pAkt) predicts biochemical recurrence. Experimental Design: Expression of PTEN and pAkt was detected by immunohistochemistry in paraffin-embedded prostate cancer tissue obtained from men undergoing radical prostatectomy. Outcome was determined by 60-month follow-up determining serum prostate-specific antigen levels. Results: By itself, PTEN was not a good predictor of biochemical recurrence; however, in combination with pAkt, it was a better predictor of the risk of biochemical recurrence compared with pAkt alone. Ninety percent of all cases with high pAkt and negative PTEN were recurrent whereas 88.2% of those with low pAkt and positive PTEN were nonrecurrent. In addition, high Gleason scores resulted in reduced protection from decreased pAkt and increased PTEN. By univariate logistic regression, pAkt alone gives an area under the receiver-operator characteristic curve of 0.82 whereas the area under the receiver-operator characteristic curve for the combination of PTEN, pAkt, and Gleason based on a stepwise selection model is 0.89, indicating excellent discrimination. Conclusions: Our results indicate that loss of PTEN expression, together with increased Akt phosphorylation and Gleason score, is of significant predictive value for determining, at the time of prostatectomy, the risk of biochemical recurrence.

AB - Purpose: A considerable fraction of patients who undergo radical prostatectomy as treatment for primary prostate cancer experience biochemical recurrence detected by elevated serum levels of prostate-specific antigen. In this study, we investigate whether loss of expression of the tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and the phosphorylated form of the cell survival protein Akt (pAkt) predicts biochemical recurrence. Experimental Design: Expression of PTEN and pAkt was detected by immunohistochemistry in paraffin-embedded prostate cancer tissue obtained from men undergoing radical prostatectomy. Outcome was determined by 60-month follow-up determining serum prostate-specific antigen levels. Results: By itself, PTEN was not a good predictor of biochemical recurrence; however, in combination with pAkt, it was a better predictor of the risk of biochemical recurrence compared with pAkt alone. Ninety percent of all cases with high pAkt and negative PTEN were recurrent whereas 88.2% of those with low pAkt and positive PTEN were nonrecurrent. In addition, high Gleason scores resulted in reduced protection from decreased pAkt and increased PTEN. By univariate logistic regression, pAkt alone gives an area under the receiver-operator characteristic curve of 0.82 whereas the area under the receiver-operator characteristic curve for the combination of PTEN, pAkt, and Gleason based on a stepwise selection model is 0.89, indicating excellent discrimination. Conclusions: Our results indicate that loss of PTEN expression, together with increased Akt phosphorylation and Gleason score, is of significant predictive value for determining, at the time of prostatectomy, the risk of biochemical recurrence.

UR - http://www.scopus.com/inward/record.url?scp=34447133479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447133479&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-0091

DO - 10.1158/1078-0432.CCR-07-0091

M3 - Article

C2 - 17606718

AN - SCOPUS:34447133479

VL - 13

SP - 3860

EP - 3867

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -